Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Comment by Aarman4on Jun 18, 2020 2:02pm
90 Views
Post# 31165881

RE:New Biosyent Interview with Bobby Kraft

RE:New Biosyent Interview with Bobby KraftI just watched it, very bullish...

Highlights:
- He is confident that next quarter will be profitable, their 40th consecutive profitable quarter.

- 2 new products being released that he expects to combine with the other offerings they have, he feels will give the company double-digit revenue growth annual for the next 8 years

- He feels the company doubling in size is very realistic within that 8 years

- He is adding talented people to his sales force, apparently their are plenty of personnel that worked for larger corps that are on the market for work now.

- They have looked at aquisitions and turned them down thus far as he couldn't see good enough returns from that process, and will instead focus on inlicensing.


Very good interview, let's hope that confidence translates on paper going forward was well!

Cheers!
<< Previous
Bullboard Posts
Next >>